New Hope for Patients: NHS Approves Life-Extending Breast Cancer Drug

Thousands of women in England living with incurable breast cancer have received life-changing news. Starting this week, the National Health Service (NHS) will provide a drug called Enhertu to patients with a specific type of advanced breast cancer known as HER2-low. This decision comes after a long period of negotiation between the government and the drug’s makers, AstraZeneca and Daiichi Sankyo.

The approval marks a significant turning point for about 1,000 women each year who will now be eligible for this treatment. According to The Guardian, the National Institute for Health and Care Excellence (Nice) — an organization that advises the NHS on which medicines offer good value for money — had previously rejected the drug in July 2024. At that time, officials felt the cost was too high to justify. However, after two years of intense campaigning by patients, cancer specialists, and charities like Breast Cancer Now, a new agreement has been reached.

This outcome is the result of what officials call a "commercial solution." The government recently changed its rules to allow the NHS to spend up to £35,000 per patient each year, an increase from the previous limit of £30,000. While it is not fully clear if the pharmaceutical companies lowered their prices, this change in policy allowed the NHS to finally approve the drug for routine use. The Guardian reports that health ministers worked behind the scenes for a long time to make this happen, aiming to bring England in line with Scotland and 27 other European countries that already provide the treatment.

For many patients, this drug offers something truly precious: more time. Clinical trials have shown that Enhertu is very effective for those whose cancer has continued to grow after other treatments. The data indicates that the drug can help patients live longer and delay the progression of their disease. While standard chemotherapy is a common treatment, Enhertu acts as a targeted therapy, meaning it delivers medicine directly to the cancer cells. According to The Guardian, the median survival time for those using the drug was 23.4 months, compared to 16.8 months for those who did not receive it.

Dr. Anne Rigg, a consultant medical oncologist and a national advisor for the NHS, described the news as "hugely positive" for women with secondary breast cancer. Similarly, Claire Rowney, the chief executive of Breast Cancer Now, called the announcement a "milestone victory." She noted that this decision will give thousands of people the opportunity to spend more time with their loved ones, which is a sentiment shared by many in the medical community.

Despite the excitement, the journey to this point was not easy. The drug’s makers had previously refused to lower their prices, which made negotiations difficult for the government. However, the persistence of campaigners kept the issue in the public eye. Yvette Cooper, the health secretary, stated that the recommendation means NHS patients will finally be able to benefit from a treatment that can be life-changing. She also noted that the success of these negotiations is a tribute to the hard work of those who fought for access to the medication.

Looking ahead, the impact of this decision is expected to spread beyond England. Ministers in Wales and Northern Ireland are likely to follow the recommendation from Nice, which would make the drug available to even more patients across the UK. This development is a clear example of how public pressure and government negotiation can work together to improve healthcare access. For the women who have been waiting for this moment, the approval of Enhertu represents a major step forward in the fight against advanced breast cancer, offering both hope and a better quality of life.